US HER2-Positive Breast Cancer Treatment Market Value Is Expected to Reach $7.95 Billion by 2023; Finds New Report
The US treatment market for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer will increase more than threefold in value, from $2.41 billion in 2013 to $7.95 billion by 2023. Latest report "PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023" states that of eight major countries, the US, France, Germany, Italy, Spain, the UK, Japan and China, the US HER2-positive breast cancer therapeutics market will expand the most, representing an impressive Compound Annual...
View full press release